brokerage reports
Jump to
157 Results Found
  • Accumulate Dr Reddy's Laboratories; target of Rs 5400: Dolat Capital Market Apr 13, 2021 01:46 PM IST

    Accumulate Dr Reddy's Laboratories; target of Rs 5400: Dolat Capital Market

    Dolat Capital Market recommended accumulate rating on Dr. Reddy's Laboratories with a target price of Rs 5400 in its research report dated April 12, 2021.

  • Buy Dr Reddy’s Laboratories: target of Rs 6500: Sharekhan Mar 05, 2021 01:34 PM IST

    Buy Dr Reddy’s Laboratories: target of Rs 6500: Sharekhan

    Sharekhan is bullish on Dr Reddy’s Laboratories has recommended buy rating on the stock with a target price of Rs 6500 in its research report dated March 04, 2021.

  • Buy Dr Reddy's Laboratories; target of Rs 5200: Dolat Capital Market Feb 09, 2021 11:48 PM IST

    Buy Dr Reddy's Laboratories; target of Rs 5200: Dolat Capital Market

    Dolat Capital Market is bullish on Dr Reddy's Laboratories has recommended buy rating on the stock with a target price of Rs 5200 in its research report dated January 31, 2021.

  • Buy Dr Reddy’s Laboratories; target of Rs 6500: Sharekhan Feb 09, 2021 10:52 PM IST

    Buy Dr Reddy’s Laboratories; target of Rs 6500: Sharekhan

    Sharekhan is bullish on Dr Reddy’s Laboratories has recommended buy rating on the stock with a target price of Rs 6500 in its research report dated January 29, 2021.

  • Cadila: COVID vaccine to be the key differentiator in the near term Feb 09, 2021 09:23 AM IST

    Cadila: COVID vaccine to be the key differentiator in the near term

    In the next fiscal, Cadila plans to launch 40-plus products, including 8-10 complex molecules which should offset pricing erosion

  • Buy Dr. Reddy's Laboratories; target of Rs 5406: Prabhudas Lilladher Feb 08, 2021 03:44 PM IST

    Buy Dr. Reddy's Laboratories; target of Rs 5406: Prabhudas Lilladher

    Prabhudas Lilladher is bullish on Dr. Reddy's Laboratories has recommended buy rating on the stock with a target price of Rs 5406 in its research report dated January 30, 2021.

  • Weekly Tactical Pick | Dr Reddy's Laboratories Feb 05, 2021 09:23 AM IST

    Weekly Tactical Pick | Dr Reddy's Laboratories

    Vaccine scope, strong product pipeline to act as tonic for Dr Reddy's Laboratories

  • Buy Dr Reddy’s Laboratories; target of Rs 5525: ICICI Direct Feb 04, 2021 05:22 PM IST

    Buy Dr Reddy’s Laboratories; target of Rs 5525: ICICI Direct

    ICICI Direct is bullish on Dr Reddy’s Laboratories has recommended buy rating on the stock with a target price of Rs 5525 in its research report dated January 30, 2021.

  • Neutral Dr Reddy’s Labs; target of Rs 5070: Motilal Oswal Feb 02, 2021 09:09 PM IST

    Neutral Dr Reddy’s Labs; target of Rs 5070: Motilal Oswal

    Motilal Oswal recommended Neutral rating on Dr Reddy’s Labs with a target price of Rs 5070 in its research report dated January 30, 2021.

  • Dr Reddy’s: Should we look beyond impairments? Jan 31, 2021 10:16 PM IST

    Dr Reddy’s: Should we look beyond impairments?

    Large part of impairment charge taken by Dr Reddy's is explained by the erosion in the value of Nuvaring due to the launch of the additional generic product by Teva

  • Gland Pharma Q3: Strong and clean play on global generic injectables; accumulate Jan 25, 2021 09:35 AM IST

    Gland Pharma Q3: Strong and clean play on global generic injectables; accumulate

    We believe dominance of profit/royalty-sharing aspect in the business model distinguishes Gland Pharma from other contract manufacturers

  • Buy Dr Reddy’s Laboratories: target of Rs 6500: Sharekhan Jan 13, 2021 01:01 PM IST

    Buy Dr Reddy’s Laboratories: target of Rs 6500: Sharekhan

    Sharekhan is bullish on Dr Reddy’s Laboratories has recommended buy rating on the stock with a target price of Rs 6500 in its research report dated January 12, 2021.

  • COVID Vaccine: The opportunities for investors - Part I Dec 11, 2020 08:32 AM IST

    COVID Vaccine: The opportunities for investors - Part I

    Vaccine rollout will throw up opportunities not just for the domestic pharmaceutical and healthcare industry but also the logistics value chain, right from vaccine production, delivery, storage and then the actual immunisation

  • Buy Dr. Reddy's; target of Rs 6050: Emkay Global Financial Nov 05, 2020 12:13 PM IST

    Buy Dr. Reddy's; target of Rs 6050: Emkay Global Financial

    Emkay Global Financial is bullish on Dr. Reddy's has recommended buy rating on the stock with a target price of Rs 6050 in its research report dated October 28, 2020.

  • Buy Dr Reddy's Laboratories; target of Rs 6000: ICICI Direct Nov 04, 2020 09:37 PM IST

    Buy Dr Reddy's Laboratories; target of Rs 6000: ICICI Direct

    ICICI Direct is bullish on Dr Reddy's Laboratories recommended buy rating on the stock with a target price of Rs 6000 in its research report dated October 29, 2020.

  • Accumulate Dr. Reddy’s laboratories; target of Rs 5418 KR Choksey Nov 04, 2020 08:53 PM IST

    Accumulate Dr. Reddy’s laboratories; target of Rs 5418 KR Choksey

    KR Choksey recommended accumulate rating on Dr. Reddy’s laboratories with a target price of Rs 5418 in its research report dated October 30, 2020.

  • Accumulate Dr Reddy's Laboratories; target of Rs 5414: Dolat Capital Market Nov 03, 2020 04:58 PM IST

    Accumulate Dr Reddy's Laboratories; target of Rs 5414: Dolat Capital Market

    Dolat Capital Market recommended accumulate rating on Dr Reddy's Laboratories with a target price of Rs 5414 in its research report dated October 28, 2020.

  • Buy Dr. Reddy's Laboratories; target of Rs 5964: Prabhudas Lilladher Nov 03, 2020 04:36 PM IST

    Buy Dr. Reddy's Laboratories; target of Rs 5964: Prabhudas Lilladher

    Prabhudas Lilladher is bullish on Dr. Reddy's Laboratories has recommended buy rating on the stock with a target price of Rs 5964 in its research report dated October 29, 2020.

  • Dr Reddy’s: Better US prospects to sustain valuations Oct 29, 2020 03:52 PM IST

    Dr Reddy’s: Better US prospects to sustain valuations

    Dr Reddy's US growth prospects have improved after its recent settlement with Bristol Myers Squibb to launch an oncology drug

  • Accumulate Dr. Reddy's Laboratories; target of Rs 5648: Prabhudas Lilladher Oct 06, 2020 12:57 PM IST

    Accumulate Dr. Reddy's Laboratories; target of Rs 5648: Prabhudas Lilladher

    Prabhudas Lilladher recommended accumulate rating on Dr. Reddy's Laboratories with a target price of Rs 5648 in its research report dated October 05, 2020.

  • Cadila: a formidable play in Covid times and beyond Sep 25, 2020 09:39 AM IST

    Cadila: a formidable play in Covid times and beyond

    Cadila is not only a credible Indian pharma striving for a Covid solution, but on a longer time scale is an interesting watch in the large-cap space witnessing a significant transformation in product portfolio.

  • Accumulate Dr. Reddy's Laboratories; target of Rs 5648: Prabhudas Lilladher Sep 24, 2020 01:56 PM IST

    Accumulate Dr. Reddy's Laboratories; target of Rs 5648: Prabhudas Lilladher

    Prabhudas Lilladher recommended accumulate rating on Dr. Reddy's Laboratories with a target price of Rs 5648 in its research report dated September 24, 2020.

  • Buy Dr Reddy’s Laboratories; target of Rs 5710: ICICI Direct Sep 21, 2020 02:36 PM IST

    Buy Dr Reddy’s Laboratories; target of Rs 5710: ICICI Direct

    ICICI Direct is bullish on Dr Reddy’s Laboratories recommended buy rating on the stock with a target price of Rs 5710 in its research report dated September 18, 2020.

  • Hold Dr. Reddy's Lab; target of Rs 5325: Emkay Global Financial Sep 18, 2020 04:52 PM IST

    Hold Dr. Reddy's Lab; target of Rs 5325: Emkay Global Financial

    Emkay Global Financial recommended hold rating on Dr. Reddy's Lab with a target price of Rs 5325 in its research report dated September 17, 2020.

  • Accumulate Dr. Reddy's Laboratories; target of Rs 4834: Dolat Capital Sep 18, 2020 01:22 PM IST

    Accumulate Dr. Reddy's Laboratories; target of Rs 4834: Dolat Capital

    Dolat Capital recommended accumulate rating on Dr. Reddy's Laboratories with a target price of Rs 4834 in its research report dated September 17, 2020.

Sections